Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Nov 30

PMID 33251134

Citations 28

Authors

Bachar Samra

Marina Konopleva

Alessandro Isidori

Naval Daver

Courtney DiNardo

Affiliations

Soon will be listed here.

Abstract

The past decade has witnessed major advances in our understanding of molecular biology, which led to breakthrough novel therapies, importantly including the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax. Notably, venetoclax-based combinations have improved outcomes, including both remission rates and overall survival, of older patients with acute myeloid leukemia (AML) deemed "unfit" for intensive chemotherapy due to age or comorbidities. This has translated into a rapid and widespread use of venetoclax-based combinations in both academic and community-based settings. Other venetoclax-based combinations are being investigated in AML with the ultimate goal of improving cure rates across many subgroups; frontline and relapsed/refractory, in combination with intensive chemotherapy, in the post-transplant setting, or as maintenance strategy. In this article, we summarize the current available data on venetoclax-based combinations. We also highlight areas of unmet medical need, and we offer practical clinical pearls for management of patients receiving such therapy.

Citing Articles

From low remission to hope: the efficacy of targeted therapies in NUP98-R positive pediatric acute myeloid leukemia.

Xiong R, Tang H, Yin T, Pan H, Jin R World J Pediatr. 2025; .

PMID: 40016600 DOI: 10.1007/s12519-025-00875-w.

Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.

Zapata Dongo R, Fontana D, Mologni L, Faya Castillo J, Infante Varillas S PLoS One. 2025; 20(1):e0308747.

PMID: 39836700 PMC: 11750102. DOI: 10.1371/journal.pone.0308747.

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines.

Kalkan F, Yildiz M, Wood N, Farid M, McCoy M, Lin M Res Sq. 2024; .

PMID: 39257974 PMC: 11384797. DOI: 10.21203/rs.3.rs-4159724/v1.

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.

Dohner H, Pratz K, DiNardo C, Wei A, Jonas B, Pullarkat V Blood. 2024; 144(21):2211-2222.

PMID: 39133921 PMC: 11600046. DOI: 10.1182/blood.2024024944.

Di Pasqua L, Abdallah M, Feletti F, Vairetti M, Ferrigno A Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675444 PMC: 11054081. DOI: 10.3390/ph17040484.

References

Chan S, Thomas D, Corces-Zimmerman M, Xavy S, Rastogi S, Hong W . Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015; 21(2):178-84. PMC: 4406275. DOI: 10.1038/nm.3788. View

Pan R, Ruvolo V, Wei J, Konopleva M, Reed J, Pellecchia M . Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015; 126(3):363-72. PMC: 4504949. DOI: 10.1182/blood-2014-10-604975. View

Chen L, Chen W, Mysliwski M, Serio J, Ropa J, Abulwerdi F . Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia. 2015; 29(6):1290-300. PMC: 4456293. DOI: 10.1038/leu.2015.18. View

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M . Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016; 34(9):972-9. DOI: 10.1200/JCO.2015.64.0060. View

Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S . Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 2019; 3(23):4043-4049. PMC: 6963254. DOI: 10.1182/bloodadvances.2019000930. View

Cheng E, Wei M, Weiler S, Flavell R, Mak T, LINDSTEN T . BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001; 8(3):705-11. DOI: 10.1016/s1097-2765(01)00320-3. View

Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View

Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G . Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clin Cancer Res. 2016; 22(17):4440-51. PMC: 5010519. DOI: 10.1158/1078-0432.CCR-15-3057. View

Pan R, Hogdal L, Benito J, Bucci D, Han L, Borthakur G . Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2013; 4(3):362-75. PMC: 3975047. DOI: 10.1158/2159-8290.CD-13-0609. View

10.

Roboz G, DiNardo C, Stein E, de Botton S, Mims A, Prince G . Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2019; 135(7):463-471. PMC: 7019193. DOI: 10.1182/blood.2019002140. View

11.

Bogenberger J, Kornblau S, Pierceall W, Lena R, Chow D, Shi C . BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014; 28(8):1657-65. PMC: 4131248. DOI: 10.1038/leu.2014.44. View

12.

Lambert J, Pautas C, Terre C, Raffoux E, Turlure P, Caillot D . Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2018; 104(1):113-119. PMC: 6312010. DOI: 10.3324/haematol.2018.188888. View

13.

Cornely O, Maertens J, Winston D, Perfect J, Ullmann A, Walsh T . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4):348-59. DOI: 10.1056/NEJMoa061094. View

14.

Nagel G, Weber D, Fromm E, Erhardt S, Lubbert M, Fiedler W . Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017; 96(12):1993-2003. PMC: 5691091. DOI: 10.1007/s00277-017-3150-3. View

15.

Seymour J, Kipps T, Eichhorst B, Hillmen P, DRozario J, Assouline S . Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018; 378(12):1107-1120. DOI: 10.1056/NEJMoa1713976. View

16.

Ramsey H, Fischer M, Lee T, Gorska A, Arrate M, Fuller L . A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov. 2018; 8(12):1566-1581. PMC: 6279595. DOI: 10.1158/2159-8290.CD-18-0140. View

17.

Wilson W, OConnor O, Czuczman M, LaCasce A, Gerecitano J, Leonard J . Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010; 11(12):1149-59. PMC: 3025495. DOI: 10.1016/S1470-2045(10)70261-8. View

18.

Wei A, Montesinos P, Ivanov V, DiNardo C, Novak J, Laribi K . Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020; 135(24):2137-2145. PMC: 7290090. DOI: 10.1182/blood.2020004856. View

19.

Guerra V, DiNardo C, Konopleva M . Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019; 32(2):145-153. PMC: 6581210. DOI: 10.1016/j.beha.2019.05.008. View

20.

Pollyea D, Tallman M, de Botton S, Kantarjian H, Collins R, Stein A . Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019; 33(11):2575-2584. PMC: 9724489. DOI: 10.1038/s41375-019-0472-2. View